SynopsisAnti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-s.....
SynopsisThis is drugs for COPD The global COPD Medicine market was valued at US$ 28670 million in 2023 and is anticipated to reach US$ 42620 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030. The global pharmaceutical market i.....
SynopsisH2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. The global Histamine H2-receptor Antagon.....
SynopsisH2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. The global H2 Antagonists or H2 blockers.....
SynopsisEpileptic Seizure Monitor System is a seizure-detection system that can be used long-term and in home situations for early intervention and prevention of seizure related side effects including SUDEP The global Epileptic Seizure Monitoring System market w.....
SynopsisIcotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mu.....
SynopsisIcotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mu.....
SynopsisAlectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). The global Alectinib Drugs market was valued at US$ 1452 million in 2023 and is anticipated to reach US$ 3171......
SynopsisRegofinil is a new type of multi-kinase small molecule inhibitor, currently it has been approved for the treatment of metastatic colorectal cancer The global Regofinil market was valued at US$ 656.9 million in 2023 and is anticipated to reach US$ 1384.8 .....
SynopsisOsimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The global Osimertinib Drugs marke.....
